1. Home
  2. RDHL vs KAVL Comparison

RDHL vs KAVL Comparison

Compare RDHL & KAVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDHL
  • KAVL
  • Stock Information
  • Founded
  • RDHL 2009
  • KAVL 1998
  • Country
  • RDHL Israel
  • KAVL United States
  • Employees
  • RDHL N/A
  • KAVL N/A
  • Industry
  • RDHL Biotechnology: Pharmaceutical Preparations
  • KAVL Medicinal Chemicals and Botanical Products
  • Sector
  • RDHL Health Care
  • KAVL Health Care
  • Exchange
  • RDHL Nasdaq
  • KAVL Nasdaq
  • Market Cap
  • RDHL 8.2M
  • KAVL 11.0M
  • IPO Year
  • RDHL N/A
  • KAVL N/A
  • Fundamental
  • Price
  • RDHL $5.85
  • KAVL $1.35
  • Analyst Decision
  • RDHL
  • KAVL
  • Analyst Count
  • RDHL 0
  • KAVL 0
  • Target Price
  • RDHL N/A
  • KAVL N/A
  • AVG Volume (30 Days)
  • RDHL 11.0K
  • KAVL 1.2M
  • Earning Date
  • RDHL 08-29-2024
  • KAVL 03-24-2025
  • Dividend Yield
  • RDHL N/A
  • KAVL N/A
  • EPS Growth
  • RDHL N/A
  • KAVL N/A
  • EPS
  • RDHL N/A
  • KAVL N/A
  • Revenue
  • RDHL $3,707,000.00
  • KAVL $10,108,906.00
  • Revenue This Year
  • RDHL $224.90
  • KAVL $652.90
  • Revenue Next Year
  • RDHL $82.69
  • KAVL N/A
  • P/E Ratio
  • RDHL N/A
  • KAVL N/A
  • Revenue Growth
  • RDHL N/A
  • KAVL N/A
  • 52 Week Low
  • RDHL $5.41
  • KAVL $0.58
  • 52 Week High
  • RDHL $20.28
  • KAVL $9.69
  • Technical
  • Relative Strength Index (RSI)
  • RDHL 40.41
  • KAVL 59.13
  • Support Level
  • RDHL $5.80
  • KAVL $1.13
  • Resistance Level
  • RDHL $6.26
  • KAVL $1.42
  • Average True Range (ATR)
  • RDHL 0.31
  • KAVL 0.17
  • MACD
  • RDHL 0.01
  • KAVL 0.00
  • Stochastic Oscillator
  • RDHL 19.33
  • KAVL 72.49

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.

About KAVL Kaival Brands Innovations Group Inc.

Kaival Brands Innovations Group Inc is focused on growing and incubating innovative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.

Share on Social Networks: